NEW YORK ( TheStreet) -- Affymax (Nasdaq: AFFY) is trading at unusually high volume Tuesday with 2.3 million shares changing hands. It is currently at 4.3 times its average daily volume and trading down 68 cents (-10.9%) at $5.58 as of 3:05 p.m. ET. Affymax has a market cap of $187.6 million and is part of the health care sector and drugs industry. Shares are down 5.9% year to date as of the close of trading on Monday. Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. TheStreet Ratings rates Affymax as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full Affymax Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.
HOST // Robert Powell
Retirement Planning Event
More from Markets
It's Hard to Be Negative When the Market Is Trading This Way
The strength in bank stocks in front of the Fed meeting is an indication there isn't real concern about an inverted yield curve.
Stocks Finish Higher Amid Concerns About Boeing and China Trade Talks
Stocks finished higher but a decline in Boeing shares limited gains.
Facebook Falls on Downgrade on Concerns More Execs Could Be Leaving
The social network's difficulty removing videos from the mass shooting in New Zealand could lead to other problems for the company, says Needham and Co.